For research use only. Not for therapeutic Use.
C12-TLRa is an adjuvant lipidoid. C12-TLRa acts as a structural component of LNP to enhance mRNA delivery. C12-TLRa substitution can increase antigen-specific antibody responses and B cell responses of clinically relevant mRNA-LNP vaccines[1].
| Catalog Number | I040994 |
| Synonyms | 1-[[4-[(4-amino-2-butylimidazo[4,5-c]quinolin-1-yl)methyl]phenyl]methyl-(2-hydroxydodecyl)amino]dodecan-2-ol |
| Molecular Formula | C46H73N5O2 |
| Purity | ≥95% |
| InChI | InChI=1S/C46H73N5O2/c1-4-7-10-12-14-16-18-20-24-39(52)35-50(36-40(53)25-21-19-17-15-13-11-8-5-2)33-37-29-31-38(32-30-37)34-51-43(28-9-6-3)49-44-45(51)41-26-22-23-27-42(41)48-46(44)47/h22-23,26-27,29-32,39-40,52-53H,4-21,24-25,28,33-36H2,1-3H3,(H2,47,48) |
| InChIKey | HIHJXHDBDZYVSP-UHFFFAOYSA-N |
| SMILES | CCCCCCCCCCC(CN(CC1=CC=C(C=C1)CN2C(=NC3=C2C4=CC=CC=C4N=C3N)CCCC)CC(CCCCCCCCCC)O)O |
| Reference | [1]. Han X, et al. Adjuvant lipidoid-substituted lipid nanoparticles augment the immunogenicity of SARS-CoV-2 mRNA vaccines. Nat Nanotechnol. 2023 Jun 26. |
